Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Atovaquone
Drug ID BADD_D00186
Description Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Indications and Usage For the treatment or prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX.
Marketing Status approved
ATC Code P01AX06
DrugBank ID DB01117
KEGG ID D00236
MeSH ID D053626
PubChem ID 74989
TTD Drug ID D06ZEE
NDC Product Code 0904-7064; 62147-0058; 0121-1796; 68462-421; 58159-048; 65977-0034; 51552-1629; 0173-0547; 62135-528; 65162-693; 69452-252; 70748-299; 65015-734; 59651-090; 63827-1005; 71052-261; 16714-900; 31722-629; 51407-642; 10702-223; 0121-0898; 60687-534; 66039-840; 0173-0665; 62147-0057; 66039-928; 66689-062; 62331-059; 50268-086
UNII Y883P1Z2LT
Synonyms Atovaquone | 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone | 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone | Wellvone | Mepron | 566C | compound 566 | 566C80 | hydroxynaphthoquinone 566C80 | 566C80 hydroxynaphthoquinone | hydroxynaphthoquinone, 566C80
Chemical Information
Molecular Formula C22H19ClO3
CAS Registry Number 94015-53-9
SMILES C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.000213%
Acute hepatic failure09.01.03.0010.000213%Not Available
Alanine aminotransferase increased13.03.04.005--
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000142%Not Available
Anxiety19.06.02.002--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Blood alkaline phosphatase13.04.02.010--Not Available
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Condition aggravated08.01.03.0040.000666%Not Available
Constipation07.02.02.001--
Cough22.02.03.0010.000142%
Death08.04.01.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.0010.000283%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.0010.000383%Not Available
Drug ineffective08.06.01.0060.000836%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Encephalopathy17.13.02.0010.000142%
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye disorder06.08.03.001--Not Available
Febrile neutropenia01.02.03.002; 08.05.02.0040.000142%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages